Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data after the market closes on Monday, May 12th. Analysts expect Arcturus Therapeutics to post earnings of ($1.10) per share and revenue of $25.64 million for the quarter.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. On average, analysts expect Arcturus Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Arcturus Therapeutics Stock Down 2.6 %
Shares of NASDAQ ARCT traded down $0.29 during mid-day trading on Wednesday, reaching $10.95. 388,478 shares of the company were exchanged, compared to its average volume of 450,132. Arcturus Therapeutics has a 52 week low of $8.04 and a 52 week high of $45.00. The company's 50 day moving average price is $12.04 and its 200 day moving average price is $15.61. The stock has a market capitalization of $296.97 million, a PE ratio of -4.93 and a beta of 2.36.
Wall Street Analyst Weigh In
ARCT has been the subject of a number of research reports. Wells Fargo & Company cut their price objective on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the company a "buy" rating in a research note on Monday, March 10th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Canaccord Genuity Group cut their price target on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Arcturus Therapeutics has a consensus rating of "Buy" and a consensus price target of $59.20.
View Our Latest Analysis on Arcturus Therapeutics
About Arcturus Therapeutics
(
Get Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Further Reading
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
